Caffeine augments proteinuria in puromycin-aminonucleoside nephrotic rats

Renal Failure

Volumn 22, Issue 2, 2000, Pages 159-179

  Tofovic, Stevan P ^a   Rominski, Barbara R ^a   Bastacky, Sheldon ^a   Jackson, Edwin K ^a   Kost Jr , Curtis K ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Adenosine; Caffeine; Chronic renal failure; Proteinuria; Renin

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; CAFFEINE; PROTEIN; PUROMYCIN AMINONUCLEOSIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COFFEE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG MECHANISM; DRUG POTENTIATION; HISTOPATHOLOGY; KIDNEY DISEASE; KIDNEY VASCULAR RESISTANCE; MALE; NEPHROTOXICITY; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEINURIA; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINARY EXCRETION;

ANIMALS; CAFFEINE; CREATININE; DISEASE PROGRESSION; DRUG SYNERGISM; KIDNEY CORTEX; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; NEPHROSIS; PHOSPHODIESTERASE INHIBITORS; PROTEINURIA; PUROMYCIN AMINONUCLEOSIDE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P1; RENIN;

EID: 0034053973     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-100100861     Document Type: Article

References (46)

1. Frenk SI, Antonowicz JM, Craig JM, Metcoff J: Experimental nephrotic syndrome induced in rats by aminonucleoside. Renal lesions and body electrolyte composition. Proc Soc Exp Biol Med 89:424-427, 1955.
2. Vernier RL, Papernaster BW. Good RA: Aminonucleoside nephrosis I. Electron microscopic study of the renal lesion in rats. J Exp Med 109:115-126, 1959.
3. Diamond JR, Karnovsky MJ: Focal and segmental glomerulosclerosis following a single intravenous dose of puromycin aminonucleoside. Am J Pathol 122:481-487, 1986.
4. Anderson S, Diamond JR, Karnowsky MJ, Brenner BM: Mechanisms Underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome. J Clin Invest 82:1757-1768, 1988.
5. Gordon J, Weening JJ, Elma JD: Glomerular sclerosis in nephrotic rats: comparison of the long-term effects of adriamycin and aminonucleoside. Lab Invest 51:277-284, 1984.
6. Classer RJ, Velosa JA, Michael A: Experimental model of focal sclerosis (I and II) Lab invest 36:519-534, 1977.
7. Derr RF, Loechler DK, Alexander CS, Nagasawa HT: Inhibition of amino-nucleoside nephrosis in rats IV: Prevention by N6-methyladenosine. J Lab Clin Med 72: 363-369, 1968.
8. Alexander CS Hunt VR: Inhibition of aminonucleoside nephrosis in rats: II Effect of nucleic acid precursors and 1-triiodothyronine. Proc Soc Exp Biol Med 108:706-709, 1961.
9. Hartman ME, Hartman JD, Baldridge RC: Inhibition of aminonucleoside nephrosis by adenine. Proc Soc Exp Biol Med 100:152-155, 1959
10. Nagase, M, Kumagai H, Honda N: Suppression of proteinuria by dipyridamole in rats with aminonucleoside nephropathy. Renal Physiol 7:218-226, 1984.
11. Nosoka K, Takahashi T, Nishi T, Imaki H, Suzuki T, Suzuki K, Kurokawa K, Endou H: An adenosine deaminase inhibitor prevents puromycin amino-nucleoside nephrotoxicity. Free Radical Bio & Med 22:597-605, 1997.
12. Aizawa T, Suzuki S, Asawa T, Komatsu M. Shigematsu, S, Okada M, Katakura, M, Hiramatsu, K, Shinoda, T, Hashizume, K Takasu, N, Yamada, T, Masaoka, Y, Mimura M, Takahashi H, Shimizu K, Honda Z: Dipyridamole reduces urinary albumin excretion in diabetic patients with normo-and microalbuminuria. Clin Nephrol 33:130-135, 1990.
13. Vallon, V, Osswald, H.: Dipyridamole prevents diabetes-induced alterations of kidney function in rats. Naun Schmi Arch Pharmacol 349:217-222, 1994.
14. De Jong PE, van der Meer, J, de Zeeuw D: Is the antiproteinuric effect of dipyridamole hemodynamically mediated? Nephron 50: 292-294, 1988.
15. Gilbert RM: Caffeine Consumption. In The Methylxanthine Beverages and Floods: Chemistry Consumption, and Health Effects, Ed. GA Spiller, Alan R. Less, Inc, New York 1984, pp 185-213.
16. Gilbert RM: Caffeine, the Most Popular Stimulant. New York, Chelsea House, 1992.
17. Kost C., LI P, Pfeifer CA, Jackson EK.: Telemetric blood pressure monitoring in benign 2-kidney, l-clip renovascular hypertension: Effect of chronic caffeine ingestion. J Pharmac Exp Therap 270:1963-1070, 1994.
18. Ohnishi A, Branch RA, Jackson K, Biaggioni I, Deray G, Jackson EK: Chronic caffeine administration exacerbates renovascular but not genetic hypertension in rats. J Clin Invest 78:1045-1050, 1986.
19. Ohnishi A, Li P, Branch RA, Biaggioni IO, Jackson EK: Adenosine in renin-dependent renovascular hypertension. Hypertension 12: 152-161, 1988
20. Choi KC, Lee J, Mood KH, Park KK, Kim SW, Kim NH: Chronic caffeine ingestion exacerbates 2-kidney, 1Clip hypertension, and ameliorates deoxycorticosterone acetate-salt hypertension in rats. Nephron, 65:619-622, 1993.
21. Tofovic SP, Kusaka I, Rominski B, Jackson E.K: Caffeine increases renal renin secretion in a rat model of genetic heart failure. J Cardiovasc Pharmacol 33:360-366, 1999.
22. Tofovic SP, Jackson EK: Effects of chronic caffeine consumption on renal function in spontaneously hypertensive heart failure prone rats. J Cardiovasc Pharmacol 33:440-450, 1999.
23. Sawynok J, Yaksh TL: Caffeine as an analgesic adjuvant: A review of pharmacology and mechanism of action. Pharmacol Rev, 45:43-85, 1993.
24. Sawynok J: Pharmacological rational for the clinical use of caffeine. Drugs, 49:1-37, 1995.
25. Daly JW: Mechanism of action of caffeine. In Caffeine, Coffee and Health, ed. Sgarattini, Raven Press, Ltd, New York , 1993, pp 97-124.
26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with theoflin phenol reagent. J Biol Chem 193:265-275, 1951.
27. Bonati M, Latini R, Tognoni G: Interspicies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat and mouse. Drug Metab Rev 15:1355-1383, 1985.
28. Holycross JB, Jackson EK. Effects of chronic treatment with caffeine on kidney responses to agiotensin II. Eur J Pharmacol 219:361-367, 1992.
29. Tunner GA, Tunner JA: Effects of chronic caffeine intake on renal function in rats with polycystic kidney disease . J Am Soc Nephr 9:383A, 1998.
30. Burton C, Harris KPG: The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 27:765-775, 1996.
31. Williams JD, Colec GA: Proteinuria - A direct cause of renal morbidity. Kidney Int 45:443-450, 1994.
32. Diamond JR, Anderson S: Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis: Amelioration by angiotensin I converting enzyme inhibition. Am J Pathol 137:1323-1332, 1990.
33. Jackson EK: Adenosine - A Physiological Brake on Renin Release. Ann Rev Pharmacol Toxicol 31:1-35, 1991.
34. Tofovic SP, Branch KR, Oliver RD, Magee WD, Jackson EK: Caffeine potentiates vasodilator induced renin release. J Pharmacol Exp Ther 256: 850-860, 1991.
35. Brown NJ, Porter J, Ryder D, Branch RA: Caffeine Potentiates the Renin Response to Diazoxide in Man. Evidence for a Regulatory Role of Endogenous Adenosine. J Pharm Exp Ther 256: 56-61, 1991.
36. Tofovic, SP, Kusaka I, Pfeifer SA, Jackson EK: Central effects of caffeine on renal renin secretion and norepinephrine spillover. J. Cardiovas. Pharmacol 28:302-313, 1996.
37. Ibrara-Rubio ME, Ramos M, Correa-Rotter R, Pedraza-Chaverri J.: Renin, prorenin, and renin gene expression in rats with acute nephrotic syndrome. Clin Exp Pharmacol Physiol 24:408-414, 1997.
38. Ibrara-Rubio ME, Ramos MV, Correa-Rotter R, Pedraza-Chaverri J: Hepatic and extrahepatic angiotensinogen gene expression ion rats with acute nephrotic syndrome. Renal Failure 19: 389-399, 1997.
39. Ichiakawa I, Harris RC: Angiotensin actions in the kidney: renewed insight into old hormone. Kid Int 40:583-596, 1991.
40. Wolf G, Neilson EG: Angiotensin II as a renal growth factor. J Am Soc Nephrol 3:1531-1540, 1993.
41. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II Stimulates Extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rats glomerular mesangial cells. J Clin Invest 93:2431-2437, 1994.
42. Eddy AA: Protein restriction reduces transforming growth factor-b and interstitial fibrosis in nephrotic syndrome. Am J Physiol 266:F884-F893, 1994.
43. 1 receptor blockade on glomerular hemodynamics: involvement of renin-angiotensin system. Am J Physiol 36:F783-F790, 1994.
44. Fogo A, Yoshida Y, Glick A, Homma T, Ichikawa I: Serial Micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest 82:322-330, 1988.
45. Lau CE, Zfalk JL: Tolerance to oral and IP caffeine: locomotor activity and pharmacokinetics. Pharmacology, Biochemistry & Behaviors, 48:337-344, 1994.
46. Statland BE, Winkel P, Bokelund H: Factors contributing to intra-individual variation of exercise and diet on variation of serum constituents in healthy subjects. Clin Chem, 19:1380-1383, 1973.